Compare Immunovant Inc. Common Stock (IMVT) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Vanguard Total World Stock Index Fund ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.5 (market cap $6.25B), while Vanguard Total World Stock Index Fund ETF trades at $159.86 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 16.3× Immunovant Inc. Common Stock's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| IMVT | VT | |
|---|---|---|
Market Cap | $6.25B | $101.70B |
Volume | 1,755,411 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $44.96 | $162.39 |
52-Week Low | $17.03 | $134.19 |
Typical Hold Time | 1 Days | 53 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vanguard Total World Stock ETF (VT) trades at $159.84, up 0.13% with a bearish technical signal from moving averages. The ETF provides exposure to over 9,700 global stocks with a 0.06% expense ratio, though key financial ratios remain unavailable. Recent news highlights VT's diversification benefits and competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF.
VT offers broad global diversification but faces headwinds from technical bearish signals and expense ratio competition. The outlook remains neutral with institutional interest mixed; risks include market volatility and geopolitical factors. Long-term investors may value its comprehensive market coverage despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
